Osborne Clarke in Amsterdam has advised Breath and existing shareholders Gimv, Sofinnova Partners, Gilde Healthcare and founders on the sale of Breath Therapeutics to Zambon for…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
